Editorial Disclaimer: TotalCareMedical.com is an independent health and wellness research publication. This is not a medical practice. The eligibility criteria discussed in this article reflect Oak Longevity's published platform information and standard obesity medicine guidance. Final eligibility for any GLP-1 medication is determined by a licensed healthcare provider after review of the patient's complete health information. Nothing in this article constitutes medical advice or a guarantee of approval.
Eligibility is the variable that decides whether a compounded-GLP-1 telehealth platform is even an option for a given patient — and it is the variable most prospective patients learn about only during the intake, after they have already evaluated the platform on price. Oak Longevity's published eligibility framework is concise but not complete; the licensed provider doing the intake review applies a fuller clinical standard than the homepage exclusions imply. This guide covers what Oak publishes, what the standard obesity medicine eligibility framework includes, what disqualifies, and what to disclose during the intake.
Our editorial team analyzed Oak Longevity's published eligibility statements, the standard clinical eligibility framework used across compounded-GLP-1 telehealth platforms, and the contraindications that apply to GLP-1 receptor agonists regardless of platform. The clinical decision to prescribe — or to decline — belongs to the licensed provider reviewing the patient's complete health information, not to a marketing comparison or an eligibility article.
What Oak Longevity Publishes
Oak Longevity's published platform information specifies three categorical exclusions: the program is not appropriate for adults under 18, individuals who are currently pregnant or nursing, or individuals with BMI under 22 and no comorbidities. Beyond these stated exclusions, Oak's eligibility model defers to the licensed provider conducting the intake review. The provider — not the platform's marketing copy — determines clinical appropriateness based on the complete patient submission.
This structure is standard across the compounded-GLP-1 telehealth category. Mochi Health, Hims, SynergyRx, and TeleHealth Med all operate on the same model: a published categorical exclusion set, plus provider-discretion review for everything within the gray zones. The variation across platforms is in how rigorously the provider review is conducted — a question covered in our Oak vs Mochi vs Hims comparison — rather than in the underlying eligibility framework itself.
The Standard Obesity Medicine Eligibility Framework
The clinical standard applied across obesity medicine, including by licensed providers on compounded-GLP-1 telehealth platforms, has two thresholds. The first threshold is body mass index of 30 or higher, classified clinically as obesity. Patients meeting this threshold are eligible for pharmacologic weight management consideration regardless of comorbid conditions. The second threshold is BMI of 27 or higher with at least one weight-related comorbid condition. Patients meeting this lower BMI threshold qualify based on the combination of overweight status and the presence of a weight-related health risk that pharmacologic intervention may address.
This dual-threshold framework appears in the FDA-approved labeling for brand-name GLP-1 medications including Wegovy and Zepbound and is the operational standard for compounded versions of the same active ingredients. The peer-reviewed STEP and SURMOUNT trial programs that established the clinical evidence base for these medications enrolled patients meeting these criteria — not patients at lower BMIs without comorbidities.
Oak's published BMI-under-22-with-no-comorbidities exclusion is therefore a partial articulation of the broader clinical standard. Patients in the 22-to-26 BMI range without comorbidities are not categorically excluded by Oak's published rules, but a responsible licensed provider applying standard obesity medicine practice will frequently decline to prescribe in this range. The decline is not a platform failure; it is appropriate clinical conservatism. GLP-1 medications carry real risks, and prescribing them outside the evidence-supported eligibility framework increases risk without proportionate benefit.
What Counts as a Weight-Related Comorbidity
The BMI 27-plus eligibility threshold requires at least one weight-related comorbid condition. The conditions typically recognized in this framework include type 2 diabetes, prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, polycystic ovary syndrome, and non-alcoholic fatty liver disease. Documentation strengthens the eligibility case substantially. A patient with a documented type 2 diabetes diagnosis supported by medical records — or a recent A1C lab value, or a current diabetes medication regimen — has a meaningfully stronger eligibility case at BMI 28 than a patient asserting “borderline blood sugar” without supporting documentation.
Patients evaluating Oak Longevity at BMI in the 27-29 range should plan to disclose specific comorbidities during the intake with as much specificity as possible. Diagnoses, A1C values, blood pressure readings, sleep study results, and lipid panel values all strengthen the case. Vague references to “feeling tired” or “concerned about diabetes” without supporting clinical documentation are unlikely to satisfy the licensed provider's review. The provider is not adversarial; the provider is applying clinical standards. Specificity helps.
For patients at BMI 30-plus, comorbidity documentation matters less for eligibility itself, but still matters for clinical management — the provider needs to know about co-existing conditions to prescribe appropriately, set realistic outcome expectations, and monitor for medication interactions.
Categorical Contraindications That Apply Everywhere
Beyond the BMI eligibility framework, GLP-1 receptor agonists carry contraindications that disqualify patients regardless of BMI or comorbidity status. These apply on Oak Longevity, on every competing compounded-GLP-1 telehealth platform, and on traditional in-person obesity medicine practices. Patients with these histories should not be approved for GLP-1 therapy, and the platform's intake should screen for them.
A personal or family history of medullary thyroid carcinoma is an absolute contraindication. The FDA-approved labeling for both semaglutide and tirzepatide carries a boxed warning related to thyroid C-cell tumors observed in animal studies. Patients with personal or family history of this rare thyroid cancer are not appropriate candidates for GLP-1 therapy.
Multiple Endocrine Neoplasia syndrome type 2 — a hereditary condition that elevates the risk of medullary thyroid carcinoma and other endocrine tumors — is the second absolute contraindication.
A history of pancreatitis is a relative contraindication that warrants particular clinical caution. GLP-1 medications have been associated with rare cases of acute pancreatitis. Patients with prior pancreatitis episodes should disclose this clearly during the intake; the provider may decline to prescribe or may prescribe with enhanced monitoring depending on the specifics.
Severe gastrointestinal disease, including gastroparesis or significant motility disorders, can be exacerbated by the slowed gastric emptying that GLP-1 medications produce. Patients with these conditions should disclose them.
Pregnancy and active attempts to conceive disqualify patients categorically. GLP-1 medications are not appropriate during pregnancy. Patients planning pregnancy should discuss the timeline with their provider; standard guidance recommends discontinuing GLP-1 therapy several months before attempting to conceive.
Active eating disorder history — particularly anorexia nervosa or bulimia — warrants careful clinical evaluation before starting GLP-1 therapy. The appetite-suppressing effect of these medications can complicate eating disorder recovery and is contraindicated during active illness.
The Intake Process — What Oak Will Ask
Oak's published intake follows the standard compounded-GLP-1 telehealth pattern: an online health questionnaire collecting medical history, current medications, weight history, lifestyle information, and screening for the contraindications above. The questionnaire is reviewed by a licensed provider who determines clinical appropriateness. If approved, a prescription is dispensed through a licensed compounding pharmacy partner with home delivery.
The questionnaire will ask about: current height and weight; goal weight; prior weight loss attempts; current medications including over-the-counter and supplements; allergies and adverse drug reactions; relevant medical history including thyroid conditions, pancreatic conditions, gastrointestinal conditions, cardiovascular conditions, mental health history including eating disorders; family history of medullary thyroid carcinoma or MEN2; pregnancy status or pregnancy plans; and lifestyle factors including alcohol use, tobacco use, and physical activity patterns.
Accurate disclosure is essential. Underreporting medical history to improve approval odds is operationally tempting and clinically dangerous. The provider's job is to prescribe safely; the patient's job is to give the provider the information needed to do that. Misrepresenting history to obtain a prescription that would not be approved with full disclosure is a path to serious adverse events that the platform's care team will not be able to address effectively because they will not know the actual clinical picture.
What Happens If the Provider Declines
If the licensed Oak provider determines that GLP-1 therapy is not clinically appropriate, the patient receives a decline rather than a prescription. The decline is not punitive; it reflects the provider's clinical judgment that the medication's risk-benefit profile does not favor treatment for this patient at this time. Common reasons for decline include: BMI in the gray zone without documented comorbidity; presence of contraindications including thyroid history; recent gastrointestinal complications; mental health history that warrants additional evaluation before GLP-1 initiation; or insufficient information in the intake to make a confident clinical decision.
Patients receiving a decline have several productive paths. The first is requesting clarification from the provider on what specifically would change the determination — sometimes additional documentation, lab work, or a coordinated discussion with the patient's primary care physician shifts the calculus. The second is seeking in-person obesity medicine evaluation, which provides a richer clinical picture than telehealth intake permits and may produce a different determination through a more thorough workup. The third is evaluating non-pharmacologic weight management strategies, including the evidence-based approaches covered in our broader Weight Management coverage.
What patients should not do is shop for a less rigorous platform. The eligibility framework exists for clinical safety reasons. A platform that approves patients other licensed providers decline is not offering more accessible care; it is operating with less clinical rigor, which is the opposite of what patients should want from a platform prescribing prescription medications.
Eligibility Verification Before Signing Up
Patients who want to evaluate likely eligibility before committing time to an intake can apply a simple framework. Calculate BMI: weight in kilograms divided by height in meters squared. BMI of 30 or higher is straightforward eligibility candidate territory. BMI of 27 to 29 with documented weight-related comorbidities is also straightforward eligibility candidate territory. BMI of 27 to 29 without documented comorbidities, or BMI under 27, is gray zone where licensed providers will frequently decline regardless of platform.
Beyond BMI, screen for the contraindications listed above. Personal or family history of medullary thyroid carcinoma or MEN2 is a categorical disqualifier. Active pregnancy or planning pregnancy in the near term disqualifies. Active eating disorder disqualifies. History of pancreatitis warrants disclosure and provider discussion before assuming eligibility.
For patients confident they meet the eligibility framework: the cost analysis covered in our Oak Longevity review, the platform comparison in our Oak vs Mochi vs Hims breakdown, the broader pricing analysis in Compounded Semaglutide Cost, and the side effect framework in Oak Longevity Side Effects are the next steps in evaluating whether Oak specifically — versus the alternatives — fits the patient's situation.
The Honest Read on Oak's Eligibility Framework
Oak Longevity's published eligibility exclusions are accurate but not complete. The licensed provider conducting intake review applies the broader clinical standard used across obesity medicine, which includes the BMI 30 or BMI 27-plus-comorbidity dual threshold and the categorical contraindications related to thyroid history, pregnancy, and pancreatic disease. Patients evaluating Oak should expect the provider review to be substantive, not a rubber stamp — and that substantive review is what makes the platform's prescriptions clinically defensible.
For patients clearly within the eligibility framework, Oak's no-membership-fee pricing structure and asynchronous intake produce a fast path from questionnaire to prescription. For patients in the gray zones, the provider's decision is the gating variable — and the platform's pricing structure does not change that decision. For patients with categorical contraindications, no compounded-GLP-1 telehealth platform is the right answer; in-person specialist evaluation is.
For broader category context and additional analysis, see our Telehealth Platform Reviews hub. The clinical decision to prescribe any GLP-1 medication, compounded or brand-name, belongs to the licensed provider — and the patient's role in that decision is honest, complete disclosure during intake.
Editorial Disclaimer: TotalCareMedical.com is an independent wellness research publication. It is not a medical practice and does not provide clinical care. All content is editorial and educational — not medical advice, diagnosis, or treatment. Eligibility criteria reflect Oak Longevity's published platform information and standard obesity medicine clinical guidance; final eligibility is determined by the licensed provider during intake review. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions and are not FDA-approved finished drugs.